Guotai Haitong rates MaxLinear Buy
Guotai Haitong published a research report on MaxLinear (MXL.US) with a Buy rating.
Related stories
Ligand Pharmaceuticals Swings to Q3 Net Loss of $28.49 Million
Ligand Pharmaceuticals reported a net loss of $28.49 million in Q3, compared with a profit a year earlier.
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Kymera Q3 Net Loss Widens as R&D Costs Rise
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
First Mid Bancshares Q3 Profit Tops Estimates on Deposit Growth
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Howmet Aerospace’s Q3 2026 Net Profit Rises 47% Year Over Year
Howmet Aerospace reported net profit up 47% year over year in the third quarter of 2026.
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
LKQ Q3 Revenue Falls 5.1%
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Verano Q3 Net Loss Narrows 91% to $4.07 Million
M impact | EQUITY | Oct 29, 2026, 11:21 AM UTC